Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Kamada Ltd (KMDA) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $8.19, with a market capitalisation of $479.57M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.50 to $9.35. This page covers its latest market performance, valuation, price trends and company information.
$479.57M | |
$8.09 | |
$17.95 | |
$3.02 | |
$8.09 | |
1.26K | |
100.48K | |
-- | |
$9.35 | |
$6.50 | |
-- | |
-- |
Kamada Ltd (KMDA) is trading at $8.19 in pre-market trading as of 2026-09-16 11:29:00, up 1.24% ($0.10) from the previous close of $8.09
Pre-market trading shows how investors are pricing KMDA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Kamada Ltd (KMDA) moved from $8.54 to $8.19, representing a decline of 4.10% ($0.35).
The stock traded between $7.90 and $8.60 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 180.93 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 59.3%
KMDA is currently trading at $8.19, placing it 59.3% of the way from its 52-week low of $6.50 to its 52-week high of $9.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
| Employees | 462 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kamada Ltd (KMDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.